IP Library Granted Patent US 10,633,367
Granted Patent B2
US 10,633,367 · App. 16/149,172 · Granted Apr 28, 2020

Fluorine- and/or deuterium-containing compounds for treating non-small cell lung cancer and related diseases

Inventors: Changfu Cheng (Northborough, MA); Shuhao Wen (Andover, MA); Hui Joyce Li (Westborough, MA)
Assignee: X-CUTAG THERAPEUTICS, INC.
C07D403/04A61P35/00C07B59/002C07B2200/05
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,633,367
App. No.
16/149,172
Granted
Apr 28, 2020
Kind
B2
Abstract

Novel fluoride and/or deuterium-containing chemical, compounds useful for treating cancer or a related disease or disorder thereof, and pharmaceutical compositions and methods of preparation and use thereof.

Claims (17)

1. A compound of the following Formula (V) or a pharmaceutically acceptable salt or ester thereof:

2. A compound of the following Formula (IX) or a pharmaceutically acceptable salt or ester thereof:

3. A compound of the following Formula (I):

wherein each of R 1 , R 2 , R 3 , R 4 , R 5 and R 6 is independently selected from the group consisting of H, F and D, and at least one of R 1 , R 2 , R 3 , R 4 , R 5 or R 6 is F, and

wherein the compound is in the form of a mesylate salt.

4. A pharmaceutical composition comprising the compound of claim 3 , and a pharmaceutically acceptable excipient, carrier, or diluent.

5. A unit dosage form comprising the pharmaceutical composition of claim 4 .

6. The compound of claim 1 , wherein the compound is in the form of a mesylate salt.

7. A pharmaceutical composition comprising the compound of claim 1 , or a pharmaceutically acceptable salt or ester thereof, and a pharmaceutically acceptable excipient, carrier, or diluent.

8. A unit dosage form comprising the pharmaceutical composition of claim 7 .

9. The compound of claim 2 , wherein the compound is in the form of a mesylate salt.

10. A pharmaceutical composition comprising the compound of claim 2 , or a pharmaceutically acceptable salt or ester thereof, and a pharmaceutically acceptable excipient, carrier, or diluent.

11. A unit dosage form comprising the pharmaceutical composition of claim 10 .

12. A pharmaceutical composition comprising the compound of claim 6 , and a pharmaceutically acceptable excipient, carrier, or diluent.

13. A unit dosage form comprising the pharmaceutical composition of claim 12 .

14. A pharmaceutical composition comprising the compound of claim 9 , and a pharmaceutically acceptable excipient, carrier, or diluent.

15. A unit dosage form comprising the pharmaceutical composition of claim 14 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 2, 2018
From: CHENG, CHANGFU; WEN, SHUHAO; LI, HUI JOYCE
To: X-CUTAG THERAPEUTICS, INC.
Reel/Frame 047032/0554 →
Continuity (2)
Provisional Application 62567379 · Oct 3, 2017
Related Publication 20190169171A1 · Jun 6, 2019